The new for-profit spinoff from the AI research group FutureHouse has raised a $70 million seed round, the latest funding behind the nascent idea of
Insmed said it is discontinuing work on Brinsupri in a form of chronic rhinosinusitis after the inflammation drug failed a Phase 2b study. The Bridgewater,
What a year! The XBI is up, M&A is bumping and the vibes are improving. But it ain’t all Christmas cookies. As has become our
Early returns suggest that Takeda’s $4 billion immunology bet appears to be paying off. Takeda said Thursday that its drug zasocitinib succeeded in two Phase
Plus, news on: Orum, FoRx, Gain Therapuetics and Antigenix: 💉 FDA approves injected version of Rybrevant: US regulators cleared a subcutaneous version of the Johnson
The White House is preparing to unveil several new deals with large drugmakers on Friday as part of the administration’s “most favored nation” pricing push, according to sources familiar with the plans.
The announcement is …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844